Key Highlights
- With the shares at 66p on 1 September 2026 according to the company's website, and 120.4m shares carrying voting rights, Venture Life is valued at roughly £79m.
- Audited accounts for an unusual 17-month period to 31 May 2026 are due on 29 September, the first full test of the slimmed-down, brand-led model.
- On 30 June 2026 Venture Life issued a trading update for the 17 months to 31 May 2026, the unusual period following its decision to move the year-end from 31 December to 31 May.
- Revenue reached £50.0m, up 30.9% on the £38.2m of the comparable prior period, or 16.0% higher on a proforma basis.
- Management said growth was "substantially Volume driven", with price contributing just 1.2 percentage points.
Venture Life Group Plc (LSE:VLG) has spent the past fourteen months quietly reinventing itself. The consumer self-care company sold its Italian Manufacturing arm for an Enterprise value of €62m in July 2025, offloaded its oral care brands in December, and on 3 June 2026 announced its first move into the United States with the $23m upfront purchase of the FemiClear and CUROXEN brands. It has also been buying back shares the board says are undervalued.
With the shares at 66p on 1 September 2026 according to the company's website, and 120.4m shares carrying voting rights, Venture Life is valued at roughly £79m. Audited accounts for an unusual 17-month period to 31 May 2026 are due on 29 September, the first full test of the slimmed-down, brand-led model.
Trading update and buyback extension: 17-month Revenue of £50.0m
On 30 June 2026 Venture Life issued a trading update for the 17 months to 31 May 2026, the unusual period following its decision to move the year-end from 31 December to 31 May. Revenue reached £50.0m, up 30.9% on the £38.2m of the comparable prior period, or 16.0% higher on a proforma basis. Management said growth was "substantially volume driven", with price contributing just 1.2 percentage points.
The final five months to 31 May 2026 showed acceleration, with revenue of £14.7m, 28.9% ahead year on year. Power Brands generated £46.7m over the 17 months, up 17.0%. Adjusted EBITDA is expected to be "in line with market guidance", though no figure was disclosed. Net cash was approximately £12.0m at 31 May 2026 after a £17.5m advance ahead of the US acquisition, and adjusted free Cash Flow for the 17 months was £5.9m.
Chief executive Jerry Randall said the group "has achieved robust double-digit growth and increased market penetration for its Power Brands". On 20 August 2026 the board extended its buyback, which had expired on 31 July, by up to 3,871,288 shares to 29 September 2026. It had already repurchased 8,933,943 shares for around £6.0m since September 2025, all held in treasury, stating that the shares are "undervalued relative to the Group's strong fundamentals and growth potential".
A US foothold: FemiClear and CUROXEN
The strategically larger event came on 3 June 2026, when Venture Life bought FemiClear and CUROXEN from Austin, Texas-based OrganiCare Nature's Sciences, LLC for $23.0m in cash at completion on 2 June, plus up to $4.0m deferred consideration tied to 2026 targets and a $1.0m earn-out for outperformance, a maximum of $28.0m, funded from existing cash.
FemiClear, around 98% of the acquired revenue, is a women's intimate health range stocked by Walmart, Walgreens, CVS and Target. In the 12 months to 31 March 2026 the brands generated net revenue of $12.1m, up 29.1%, Gross Profit of $7.5m and a contribution of $3.6m. Randall called them "highly complementary" and "margin enhancing", giving Venture Life a platform in what it estimates is a $0.7bn US feminine treatment market.
What Venture Life does now
Venture Life develops and markets consumer self-care products, split between medical devices and nutritional supplements, sold mainly through UK pharmacy, grocery and online channels alongside an international distributor business. After selling its contract manufacturing (CDMO) operation to Healthea Group's BioDue S.p.A. and the Ultradex and Dentyl oral care brands for up to £4.5m, the group is centred on its Power Brands: Balance Activ in women's intimate health, Health & Her and Health & Him in hormone health, Earol in ear care, and Lift and Glucogel in glucose management.
Over the 17 months Balance Activ delivered £12.2m (up 15.1%), Health & Her/Him £11.8m (up 28.2%), Lift £11.0m (up 19.6%), Earol £8.2m (up 7.9%) and Glucogel £3.5m (up 6.1%). Health & Her, acquired in November 2024, is the UK's number one menopause supplement Brand according to Circana data cited by the company.
Calendar 2025 results: revenue up 32%, Balance Sheet transformed
The most recent detailed figures are the unaudited results for the 12 months to 31 December 2025, published on 31 March 2026 and labelled interims because of the year-end change. Continuing revenue rose 32.2% to £35.2m from £26.6m, with 14.9% proforma growth from the Power Brands. UK revenue climbed 17.3% proforma to £25.0m, while international sales slipped 1.9% to £10.1m. Gross Margin eased to 45.0% from 45.8%.
Profitability was more mixed. Adjusted EBITDA fell 3.6% to £6.0m, the margin dropping to 16.9% from 23.2% as the company deliberately stepped up UK Advertising spend. On a statutory basis the continuing Business recorded an operating loss of £1.3m against a £1.5m profit in 2024 and a pre-tax loss of £1.9m, reflecting exceptional and restructuring costs. Adjusted profit before tax rose 14.0% to £4.9m. Discontinued operations added £8.0m of profit, including an £11.4m disposal gain, lifting Basic Earnings Per Share to 4.79p from a 0.25p loss.
The balance sheet shows the transformation most clearly: cash of £34.2m at 31 December 2025 compared with net Debt of £19.9m a year earlier, with a £30m revolving Credit Facility undrawn. Free cash flow was £3.3m, or £5.1m before exceptional costs. No Dividend was declared.
What could drive the shares next
The 29 September 2026 audited results are the immediate catalyst, providing the first adjusted EBITDA figure for the 17-month period and, potentially, guidance for the year to May 2027 including a full FemiClear contribution. Evidence of early US sell-through would strengthen the case. Management continues to explore "earning enhancing M&A opportunities", and the buyback runs to the results date.
Risks investors should watch
The US expansion is the largest single risk. Venture Life has no track record in American retail, where slotting costs, returns and promotional demands can erode margins. The Acquisition consumed much of the cash from the CDMO sale, leaving net cash of around £12.0m and adding dollar exposure for a sterling reporter. Statutory profitability lags adjusted measures, and heavier Marketing spend compressed the EBITDA margin in 2025; investors will want that spend to convert into durable share gains. International sales slipped in 2025, and having sold its factory the group now depends on third-party supply. The stock's limited liquidity, acknowledged in the buyback terms, can also amplify price moves.
Outlook
Venture Life enters its new financial calendar as a smaller, brand-focused business with a stronger balance sheet than in recent years and a first foothold in the world's largest consumer health market. Double-digit volume-led growth, a self-funded US acquisition and a board buying back stock make the "overlooked" label at least worth debating. The audited 17-month results on 29 September will show whether adjusted EBITDA has kept pace with revenue and how much cash remains for further deals. Shareholders should watch the US integration and margin recovery before drawing firmer conclusions.






Please wait processing your request...